Villar V - Search Results

1

ROS-NFkappaB mediates TGF-beta1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion.

Tobar N, Villar V, Santibanez JF. Tobar N, et al. Among authors: villar v. Mol Cell Biochem. 2010 Jul;340(1-2):195-202. doi: 10.1007/s11010-010-0418-5. Epub 2010 Mar 5. Mol Cell Biochem. 2010. PMID: 20204677

2

Spred2 inhibits TGF-beta1-induced urokinase type plasminogen activator expression, cell motility and epithelial mesenchymal transition.

Villar V, Kocić J, Santibanez JF. Villar V, et al. Int J Cancer. 2010 Jul 1;127(1):77-85. doi: 10.1002/ijc.25045. Int J Cancer. 2010. PMID: 19908229

3

SKIP is required for TGF-β1-induced epithelial mesenchymal transition and migration in transformed keratinocytes.

Villar V, Kocic J, Bugarski D, Jovcic G, Santibanez JF. Villar V, et al. FEBS Lett. 2010 Nov 19;584(22):4586-92. doi: 10.1016/j.febslet.2010.10.020. Epub 2010 Oct 19. FEBS Lett. 2010. PMID: 20965173 Free article.

4

Skip Regulates TGF- β 1-Induced Extracellular Matrix Degrading Proteases Expression in Human PC-3 Prostate Cancer Cells.

Villar V, Kocic J, Santibanez JF. Villar V, et al. Prostate Cancer. 2013;2013:398253. doi: 10.1155/2013/398253. Epub 2013 May 20. Prostate Cancer. 2013. PMID: 23766912 Free PMC article.

5

SKIP Downregulation Increases TGF-β1-Induced Matrix Metalloproteinase-9 Production in Transformed Keratinocytes.

Kocić J, Villar V, Krstić A, Santibanez JF. Kocić J, et al. Among authors: villar v. Scientifica (Cairo). 2012;2012:861647. doi: 10.6064/2012/861647. Epub 2012 Aug 2. Scientifica (Cairo). 2012. PMID: 24278749 Free PMC article.

6

The Metabolic Features of Tumor-Associated Macrophages: Opportunities for Immunotherapy?

Mojsilovic SS, Mojsilovic S, Villar VH, Santibanez JF. Mojsilovic SS, et al. Anal Cell Pathol (Amst). 2021 Aug 14;2021:5523055. doi: 10.1155/2021/5523055. eCollection 2021. Anal Cell Pathol (Amst). 2021. PMID: 34476174 Free PMC article. Review.

7

Current and Future Cancer Chemoprevention Strategies.

Santibanez JF, Villar VH, Echeverria C. Santibanez JF, et al. Among authors: villar vh. Pharmaceutics. 2023 May 19;15(5):1543. doi: 10.3390/pharmaceutics15051543. Pharmaceutics. 2023. PMID: 37242785 Free PMC article.

8

Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas.

Villar VH, Vögler O, Martínez-Serra J, Ramos R, Calabuig-Fariñas S, Gutiérrez A, Barceló F, Martín-Broto J, Alemany R. Villar VH, et al. PLoS One. 2012;7(5):e37735. doi: 10.1371/journal.pone.0037735. Epub 2012 May 25. PLoS One. 2012. PMID: 22662203 Free PMC article.

9

Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein.

Villar VH, Vögler O, Barceló F, Gómez-Florit M, Martínez-Serra J, Obrador-Hevia A, Martín-Broto J, Ruiz-Gutiérrez V, Alemany R. Villar VH, et al. J Nutr Biochem. 2014 Apr;25(4):429-38. doi: 10.1016/j.jnutbio.2013.12.003. Epub 2013 Dec 31. J Nutr Biochem. 2014. PMID: 24491315

10

Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma.

Alemany R, Moura DS, Redondo A, Martinez-Trufero J, Calabuig S, Saus C, Obrador-Hevia A, Ramos R, Villar VH, Valverde C, Vaz MA, Medina J, Felipe-Abrio I, Hindi N, Taron M, Martin-Broto J. Alemany R, et al. Clin Cancer Res. 2018 Nov 1;24(21):5239-5249. doi: 10.1158/1078-0432.CCR-18-0851. Epub 2018 Jul 23. Clin Cancer Res. 2018. PMID: 30037815 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

165 results

Search Page

Filters